This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stadler, W. M. Articles by Olopade, O. I. Search for Related Content PubMed PubMed Citation Articles by Stadler, W. M. Articles by Olopade, O. I.

Homozygous Deletions within Chromosomal Bands 9p21–22 in Bladder Cancer¹

Sections of Hematology/Oncology [W. M. S., J. S., S. K. B., D. Ro., M. D., O. I. O.] and Urology [D. Ru.], University of Chicago, Chicago, Illinois 60637

The loss of DNA sequences on chromosomal bands 9p21–22 has been documented in a variety of malignancies including leukemias, gliomas, lung cancers, and melanomas. Because of the high incidence of monosomy 9 detected by both cytogenetics and loss of heterozygosity studies in bladder cancer, we examined seven bladder cancer cell lines for deletions in this region. Using seven DNA probes that span the region of 9p21–22 as well as a functional assay for methylthioadenosine phosphorylase (MTAP), which maps to 9p21, we found four cell lines that had small homozygous deletions. These deletions map centromeric to the interferon (IFN) gene cluster and telomeric to D9S171. Only one of the cell lines with deletions had a cytogenetically evident lesion in this chromosomal region. Preliminary loss of heterozygosity studies with 10 primary bladder cancer specimens using 10 markers spanning chromosome 9 revealed loss of heterozygosity at the IFN locus with retention of heterozygosity with more centromeric 9p markers and all informative 9q markers in the tumor of one patient. These data suggest that loss of a tumor suppressor gene on 9p21–22, which may represent a general pathway of oncogenesis, is important in bladder cancer development.

¹ Supported in part by James S. McDonnell Foundation Award #92-51 (O. I. O.).

² To whom requests for reprints should be addressed, at University of Chicago Medical Center, Section of Hematology/Oncology, MC 2115, 5841 S. Maryland Avenue, Chicago, IL 60637-1470.

Received 12/ 2/93. Accepted 3/ 4/94.

This article has been cited by other articles:

				T. Bonome, D. A. Levine, J. Shih, M. Randonovich, C. A. Pise-Masison, F. Bogomolniy, L. Ozbun, J. Brady, J. C. Barrett, J. Boyd, et al. A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer Cancer Res., July 1, 2008; 68(13): 5478 - 5486. [Abstract] [Full Text] [PDF]

				M. J. Worsham, K. M. Chen, N. Tiwari, G. Pals, J. P. Schouten, S. Sethi, and M. S. Benninger Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, April 1, 2006; 132(4): 409 - 415. [Abstract] [Full Text] [PDF]

				J. S. Aveyard and M. A. Knowles Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification J. Mol. Diagn., November 1, 2004; 6(4): 356 - 365. [Abstract] [Full Text] [PDF]

				S. A. Christopher, P. Diegelman, C. W. Porter, and W. D. Kruger Methylthioadenosine Phosphorylase, a Gene Frequently Codeleted with p16cdkN2a/ARF, Acts as a Tumor Suppressor in a Breast Cancer Cell Line Cancer Res., November 15, 2002; 62(22): 6639 - 6644. [Abstract] [Full Text] [PDF]

				A. H. N. Hopman, M. A. F. Kamps, E. J. M. Speel, R. F. M. Schapers, G. Sauter, and F. C. S. Ramaekers Identification of Chromosome 9 Alterations and p53 Accumulation in Isolated Carcinoma in Situ of the Urinary Bladder versus Carcinoma in Situ Associated with Carcinoma Am. J. Pathol., October 1, 2002; 161(4): 1119 - 1125. [Abstract] [Full Text] [PDF]

				H. Momoi, H. Okabe, T. Kamikawa, S. Satoh, I. Ikai, M. Yamamoto, A. Nakagawara, Y. Shimahara, Y. Yamaoka, and M. Fukumoto Comprehensive Allelotyping of Human Intrahepatic Cholangiocarcinoma Clin. Cancer Res., September 1, 2001; 7(9): 2648 - 2655. [Abstract] [Full Text] [PDF]

				B. Tang, Y. N. Li, and W. D. Kruger Defects in Methylthioadenosine Phosphorylase Are Associated with but not Responsible for Methionine-dependent Tumor Cell Growth Cancer Res., October 1, 2000; 60(19): 5543 - 5547. [Abstract] [Full Text]

				I. A. Sokolova, K. C. Halling, R. B. Jenkins, H. M. Burkhardt, R. G. Meyer, S. A. Seelig, and W. King The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in Urine J. Mol. Diagn., August 1, 2000; 2(3): 116 - 123. [Abstract] [Full Text]

				S. Sarkar, K. P. Jülicher, M. S. Burger, V. Della Valle, C.-J. Larsen, T. R. Yeager, T. B. Grossman, R. W. Nickells, C. Protzel, D. F. Jarrard, et al. Different Combinations of Genetic/Epigenetic Alterations Inactivate the p53 and pRb Pathways in Invasive Human Bladder Cancers Cancer Res., July 1, 2000; 60(14): 3862 - 3871. [Abstract] [Full Text]

				C A Reznikoff, C Belair, E Savelieva, Y Zhai, K Pfeifer, T Yeager, K J Thompson, S DeVries, C Bindley, and M A Newton Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes & Dev., September 15, 1994; 8(18): 2227 - 2240. [Abstract] [PDF]